Novel Solutions for the Quantification and Characterisation of Polymorphs and Amorphous Form
Register to download slides & media
Additional Documents
Overview
Patent expiration is a threat for pharmaceutical industry and an opportunity for generic companies. In average, there is a 90% decrease of revenue after the patent expiration of a drug. There are different strategies to line extension such as combination therapies, new medical applications, a new isomer, different dosing and new solid forms (crystalline or amorphous). Millions are spent by drug originators and generics firms on intellectual property lawsuits dealing with solid form. When this happens, you want the best data in your hands!
In general, different polymorphs show different physicochemical characteristics and properties. Therefore, the selection of the API form for drug product (DP) development is more than critical because the API form itself has a great impact on the properties of the final DP: the form selection problem has ethic, therapeutics, commercial and economic implications.
Solutions to polymorphs and amorphous forms characterisation and quantification will be evaluated including in house or synchrotron based powder X-Ray diffraction with its application to ordered and disordered materials, solid state NMR (ssNMR) and relaxometry by time-domain NMR (TD-NMR). Join us to hear about disruptive game-changers such as the new cryogenic probe for ssNMR with a 3-fold sensitivity increase or the minipec FromCheck benchtop. Get ahead of the game!
What to expect
In this webinar Dr Matteo Daldosso, Aptuit and Dr. Sebastian Wegner and Dr. Anna Codina, Bruker BioSpin, will discuss novel solutions for solid form characterisation and quantification.
Key topics
- Dramatically improving your productivity with the new CryoProbe for solids
- Increasing throughput with the walk-up solid-state NMR lab
- Decreasing amorphous form LOQ with the benchtop TD-NMR relaxometer
Who should attend?
This webinar will be of interest to those looking to extend and improve their analytical capabilities, heads of solid form characterisation, analytical and chemical R&D, laboratory managers and expert users of complementary technologies. It is especially dedicated for those seeking to understand the return of investment in novel solutions that play a critical role in the market exclusivity of therapeutic drugs and therefore heavily impact revenue.
Speakers
After her post-doc she worked in the Analytical R&D department of Pfizer, UK, for 8 years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation.
She joined Bruker in 2011 as Material Characterisation Laboratory Manager. Since then her role has evolved. She started looking after the pharmaceutical market in 2015 as Product Portfolio Manager. She is now director of the pharmaceutical business Unit at Bruker BioSpin.
www.aptuit.com